Literature DB >> 30442067

A novel synthetic cannabinoid (Cumyl-4-cyano-BINACA) resulting in hyperthermia, rhabdomyolysis, and renal failure in a 29-year-old patient: it's not meningitis.

Tharwat El Zahran1, Roy Gerona2, Brent W Morgan1, Adam C Pomerleau1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30442067     DOI： 10.1080/15563650.2018.1534241

Source DB:  PubMed          Journal:  Clin Toxicol (Phila)        ISSN： 1556-3650            Impact factor:   4.467


× No keyword cloud information.
  4 in total

Review 1.  Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2017-2020: A Review.

Authors:  Amanda L A Mohr; Barry K Logan; Melissa F Fogarty; Alex J Krotulski; Donna M Papsun; Sherri L Kacinko; Marilyn A Huestis; Jeri D Ropero-Miller
Journal:  J Anal Toxicol       Date:  2022-07-14       Impact factor: 3.220

2.  Behavioral pharmacology of five novel synthetic cannabinoids.

Authors:  Michael B Gatch; Andrew Tourigny; Ritu A Shetty; Michael J Forster
Journal:  Behav Pharmacol       Date:  2022-04-01       Impact factor: 2.293

3.  CUMYL-4CN-BINACA Is an Efficacious and Potent Pro-Convulsant Synthetic Cannabinoid Receptor Agonist.

Authors:  Richard C Kevin; Lyndsey Anderson; Iain S McGregor; Rochelle Boyd; Jamie J Manning; Michelle Glass; Mark Connor; Samuel D Banister
Journal:  Front Pharmacol       Date:  2019-05-29       Impact factor: 5.810

Review 4.  Designer drugs: mechanism of action and adverse effects.

Authors:  Dino Luethi; Matthias E Liechti
Journal:  Arch Toxicol       Date:  2020-04-06       Impact factor: 5.153
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.